NeuroPace, Inc. (NASDAQ:NPCE) Given Average Recommendation of “Moderate Buy” by Analysts

NeuroPace, Inc. (NASDAQ:NPCE) has been assigned an average recommendation of “Moderate Buy” from the seven analysts that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $15.67.

A number of analysts have recently commented on the company. Wells Fargo & Company raised NeuroPace from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $16.00 to $20.00 in a research report on Thursday, March 14th. Morgan Stanley increased their target price on NeuroPace from $9.00 to $13.00 and gave the stock an “equal weight” rating in a research note on Wednesday, March 6th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $18.00 price target on shares of NeuroPace in a research report on Thursday, May 9th.

Insider Transactions at NeuroPace

In related news, major shareholder Orbimed Advisors Llc sold 4,674 shares of NeuroPace stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $14.03, for a total value of $65,576.22. Following the completion of the sale, the insider now directly owns 3,406,335 shares in the company, valued at approximately $47,790,880.05. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders sold 525,345 shares of company stock worth $7,583,250 over the last quarter. 22.20% of the stock is currently owned by insiders.

Institutional Investors Weigh In On NeuroPace

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Barclays PLC lifted its holdings in shares of NeuroPace by 9,085.6% during the 3rd quarter. Barclays PLC now owns 10,839 shares of the company’s stock valued at $105,000 after buying an additional 10,721 shares during the period. Kent Lake Capital LLC increased its position in NeuroPace by 285.0% during the third quarter. Kent Lake Capital LLC now owns 574,417 shares of the company’s stock valued at $5,589,000 after acquiring an additional 425,212 shares during the last quarter. Citigroup Inc. bought a new position in NeuroPace in the third quarter valued at about $29,000. Vanguard Group Inc. boosted its position in NeuroPace by 18.3% in the first quarter. Vanguard Group Inc. now owns 488,618 shares of the company’s stock worth $6,450,000 after purchasing an additional 75,512 shares during the last quarter. Finally, Acadian Asset Management LLC bought a new stake in shares of NeuroPace during the 1st quarter valued at about $621,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

NeuroPace Trading Down 1.2 %

NASDAQ NPCE opened at $7.23 on Friday. The stock’s 50 day moving average is $8.56 and its 200 day moving average is $11.84. The company has a quick ratio of 5.56, a current ratio of 6.43 and a debt-to-equity ratio of 4.05. The firm has a market capitalization of $208.01 million, a PE ratio of -6.08 and a beta of 1.80. NeuroPace has a twelve month low of $3.91 and a twelve month high of $18.15.

NeuroPace (NASDAQ:NPCE) last released its earnings results on Wednesday, May 8th. The company reported ($0.32) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.32). NeuroPace had a negative net margin of 45.61% and a negative return on equity of 173.62%. The firm had revenue of $18.12 million for the quarter, compared to the consensus estimate of $18.12 million. Research analysts forecast that NeuroPace will post -1.14 earnings per share for the current fiscal year.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.